Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease
Identifieur interne : 008A37 ( Main/Merge ); précédent : 008A36; suivant : 008A38Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease
Auteurs : R. Inzelberg [Israël] ; P. Nisipeanu [Israël] ; M. J. Rabey [Israël] ; Korczyn [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 1995-09.
English descriptors
- KwdEn :
- Aged, Cabergoline, Dopamine Agonists (administration & dosage), Dopamine Agonists (therapeutic use), Dopamine agonist, Drug Tolerance, Dyskinesia, Drug-Induced, Dyskinesias, Edema (chemically induced), Ergolines (administration & dosage), Ergolines (adverse effects), Ergolines (therapeutic use), Female, Humans, Male, Middle Aged, Motor fluctuations, On‐off phenomenon, Parkinson Disease (drug therapy), Parkinson's disease.
- MESH :
- chemical , administration & dosage : Dopamine Agonists, Ergolines.
- chemical , adverse effects : Ergolines.
- chemical , therapeutic use : Dopamine Agonists, Ergolines.
- chemically induced : Edema.
- drug therapy : Parkinson Disease.
- Aged, Drug Tolerance, Dyskinesia, Drug-Induced, Female, Humans, Male, Middle Aged.
Abstract
Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.
Url:
DOI: 10.1002/mds.870100512
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003480
- to stream Istex, to step Curation: 003480
- to stream Istex, to step Checkpoint: 003D06
- to stream PubMed, to step Corpus: 004933
- to stream PubMed, to step Curation: 004933
- to stream PubMed, to step Checkpoint: 004959
- to stream Ncbi, to step Merge: 004A50
- to stream Ncbi, to step Curation: 004A50
- to stream Ncbi, to step Checkpoint: 004A50
Links to Exploration step
ISTEX:1B71BE52B29898357761470FADAF3A01837AAFD0Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name></author><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1B71BE52B29898357761470FADAF3A01837AAFD0</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100512</idno><idno type="url">https://api.istex.fr/document/1B71BE52B29898357761470FADAF3A01837AAFD0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003480</idno><idno type="wicri:Area/Istex/Curation">003480</idno><idno type="wicri:Area/Istex/Checkpoint">003D06</idno><idno type="wicri:doubleKey">0885-3185:1995:Inzelberg R:long:term:tolerability</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8552112</idno><idno type="wicri:Area/PubMed/Corpus">004933</idno><idno type="wicri:Area/PubMed/Curation">004933</idno><idno type="wicri:Area/PubMed/Checkpoint">004959</idno><idno type="wicri:Area/Ncbi/Merge">004A50</idno><idno type="wicri:Area/Ncbi/Curation">004A50</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A50</idno><idno type="wicri:doubleKey">0885-3185:1995:Inzelberg R:long:term:tolerability</idno><idno type="wicri:Area/Main/Merge">008A37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-09">1995-09</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="604">604</biblScope><biblScope unit="page" to="607">607</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1B71BE52B29898357761470FADAF3A01837AAFD0</idno><idno type="DOI">10.1002/mds.870100512</idno><idno type="ArticleID">MDS870100512</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Cabergoline</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine agonist</term><term>Drug Tolerance</term><term>Dyskinesia, Drug-Induced</term><term>Dyskinesias</term><term>Edema (chemically induced)</term><term>Ergolines (administration & dosage)</term><term>Ergolines (adverse effects)</term><term>Ergolines (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor fluctuations</term><term>On‐off phenomenon</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term><term>Ergolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ergolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Ergolines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Edema</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Tolerance</term><term>Dyskinesia, Drug-Induced</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.</div></front></TEI><double doi="10.1002/mds.870100512"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name></author><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1B71BE52B29898357761470FADAF3A01837AAFD0</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100512</idno><idno type="url">https://api.istex.fr/document/1B71BE52B29898357761470FADAF3A01837AAFD0/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003480</idno><idno type="wicri:Area/Istex/Curation">003480</idno><idno type="wicri:Area/Istex/Checkpoint">003D06</idno><idno type="wicri:doubleKey">0885-3185:1995:Inzelberg R:long:term:tolerability</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R." last="Inzelberg">R. Inzelberg</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P." last="Nisipeanu">P. Nisipeanu</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M. J." last="Rabey">M. J. Rabey</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel‐Aviv University, Ramat‐Aviv</wicri:regionArea><wicri:noRegion>Ramat‐Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-09">1995-09</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="604">604</biblScope><biblScope unit="page" to="607">607</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1B71BE52B29898357761470FADAF3A01837AAFD0</idno><idno type="DOI">10.1002/mds.870100512</idno><idno type="ArticleID">MDS870100512</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cabergoline</term><term>Dopamine agonist</term><term>Dyskinesias</term><term>Motor fluctuations</term><term>On‐off phenomenon</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half‐life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for >1 year (up to 39 months). The motor status ameliorated and the percentage of “off” hours significantly decreased in the first year and did not increase significantly later during long‐term follow‐up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R" last="Inzelberg">R. Inzelberg</name><affiliation wicri:level="1"><nlm:affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P" last="Nisipeanu">P. Nisipeanu</name></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M J" last="Rabey">M J Rabey</name></author><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8552112</idno><idno type="pmid">8552112</idno><idno type="doi">10.1002/mds.870100512</idno><idno type="wicri:Area/PubMed/Corpus">004933</idno><idno type="wicri:Area/PubMed/Curation">004933</idno><idno type="wicri:Area/PubMed/Checkpoint">004959</idno><idno type="wicri:Area/Ncbi/Merge">004A50</idno><idno type="wicri:Area/Ncbi/Curation">004A50</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A50</idno><idno type="wicri:doubleKey">0885-3185:1995:Inzelberg R:long:term:tolerability</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.</title><author><name sortKey="Inzelberg, R" sort="Inzelberg, R" uniqKey="Inzelberg R" first="R" last="Inzelberg">R. Inzelberg</name><affiliation wicri:level="1"><nlm:affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv</wicri:regionArea><wicri:noRegion>Ramat-Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Nisipeanu, P" sort="Nisipeanu, P" uniqKey="Nisipeanu P" first="P" last="Nisipeanu">P. Nisipeanu</name></author><author><name sortKey="Rabey, M J" sort="Rabey, M J" uniqKey="Rabey M" first="M J" last="Rabey">M J Rabey</name></author><author><name sortKey="Korczyn, A D" sort="Korczyn, A D" uniqKey="Korczyn A" first="A D" last="Korczyn">A D Korczyn</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Tolerance</term><term>Dyskinesia, Drug-Induced</term><term>Edema (chemically induced)</term><term>Ergolines (administration & dosage)</term><term>Ergolines (adverse effects)</term><term>Ergolines (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agonists</term><term>Ergolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ergolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Ergolines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Edema</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Tolerance</term><term>Dyskinesia, Drug-Induced</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half-life of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a long half-life and can be given in a single daily dose. Seventeen patients with severe fluctuations were treated with cabergoline, seven of them for > 1 year (up to 39 months). The motor status ameliorated and the percentage of "off" hours significantly decreased in the first year and did not increase significantly later during long-term follow-up. Cabergoline is a promising treatment for parkinsonian patients with motor fluctuations.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008A37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 008A37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:1B71BE52B29898357761470FADAF3A01837AAFD0
|texte= Long‐term tolerability and efficacy of cabergoline, a new long‐acting dopamine agonist, in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |